The future of biopharma started in a basement

We started with a question: What if there was a better way to create new medicines?

From a basement in Portland, we engineered E. coli, biopharma’s original host organism, to be an effective factory for complex human proteins. But we didn’t stop there.

We built our technology to enable better, faster, smarter biologic drug discovery and cell line development. We call it Integrated Drug Creation™.

Get to know us.

Ideas to Impact

Absci is unlocking the potential of next-generation biologics by harnessing deep learning AI and synthetic biology to explore a vast therapeutic sequence space inaccessible to conventional discovery methods.


Meet the Team

  • Leadership Team
  • Executive Leadership
  • Board of Directors

Sean McClain

Founder, CEO & Director

Matthew Weinstock, PhD

Chief Technology Officer

Greg Schiffman, CPA

Chief Financial Officer

Sarah Korman, PhD, JD

Chief Legal Officer

Denise Dettore

Chief People Officer

Jack Gold

Chief Marketing Officer

Penelope

Chief Morale Officer

Todd Bedrick, CPA

SVP, Chief Accounting Officer

Deniz Kural, PhD

SVP, Antibody & Target Discovery

James Sietstra

SVP, Business Development

Jonathan Eads, MS

SVP, Informatics

Jens Plassmeier, PhD

SVP, Synthetic Biology R&D

Thomas Wrona, PhD, JD

SVP, Intellectual Property

Kate Corcoran, PhD

VP, Investor Relations

Imad Ajjawi, PhD, MBA

VP, Business Development

Daniele Biasci, PhD

Consulting VP, Immunology

Translate ideas into drugs.

Explore current openings and get ready to prove that impossible isn’t.

Join us